Trial Profile
A randomised, two-arm, multicentre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms ICON-7
- 21 Sep 2020 Results assess the role of KELIM regarding the probability of long progression-free survivorship (PS) > 5 years after 1st line treatment (AGO-OVAR 9; AGO-OVAR 7 and ICON 7) presented at the 45th European Society for Medical Oncology Congress
- 01 Apr 2019 Results validating the higher predictive & prognostic values of KELIM during first line treatments in ovarian cancer patients published in the Clinical Cancer Research
- 15 Nov 2018 Results (data cut-off 30 Nov 2010) assessing primary Progression Free Survival analysis, published in the Gynecologic Oncology